← Back to Screener
Delcath Systems Inc (DCTH)
Price$10.88
Favorite Metrics
Price vs S&P 500 (26W)-4.92%
Price vs S&P 500 (4W)10.24%
Market Capitalization$377.34M
P/E Ratio (Annual)139.76x
All Metrics
P/CF (Annual)16.76x
Book Value / Share (Quarterly)$3.21
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)215.27%
Cash Flow / Share (Quarterly)$0.60
Price vs S&P 500 (YTD)3.39%
Gross Margin (TTM)86.16%
Net Profit Margin (TTM)3.17%
EPS (TTM)$0.06
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$0.06
Revenue Growth (5Y)120.10%
EPS (Annual)$0.07
ROI (Annual)2.43%
Gross Margin (Annual)86.16%
Net Profit Margin (5Y Avg)-887.88%
Cash / Share (Quarterly)$2.62
P/E Basic Excl Extra (TTM)139.76x
Revenue Growth QoQ (YoY)37.27%
P/E Normalized (Annual)139.76x
ROA (Last FY)2.18%
Revenue Growth TTM (YoY)129.08%
EBITD / Share (TTM)$0.02
ROE (5Y Avg)-132.44%
Operating Margin (TTM)0.77%
Cash Flow / Share (Annual)$0.60
P/B Ratio3.39x
P/B Ratio (Quarterly)3.21x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.92x
Net Interest Coverage (TTM)-32.13x
ROA (TTM)2.39%
EPS Growth QoQ (YoY)-64.06%
EV / EBITDA (TTM)403.25x
EPS Incl Extra (Annual)$0.07
Current Ratio (Annual)10.92x
Quick Ratio (Quarterly)9.69x
3-Month Avg Trading Volume0.45M
52-Week Price Return-5.97%
EV / Free Cash Flow (Annual)15.92x
P/E Incl Extra (TTM)139.76x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)4.43x
Asset Turnover (Annual)0.69x
52-Week High$18.23
Operating Margin (5Y Avg)-763.03%
EPS Excl Extra (Annual)$0.07
CapEx CAGR (5Y)14.68%
26-Week Price Return3.82%
Quick Ratio (Annual)9.69x
13-Week Price Return4.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.92x
Enterprise Value$333.89
Revenue / Share Growth (5Y)30.28%
Asset Turnover (TTM)0.75x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.37x
Pretax Margin (Annual)4.12%
Cash / Share (Annual)$2.62
3-Month Return Std Dev50.52%
Gross Margin (5Y Avg)78.86%
Net Income / Employee (TTM)$0
ROE (Last FY)2.43%
Net Interest Coverage (Annual)-65.17x
EPS Basic Excl Extra (Annual)$0.07
P/FCF (TTM)18.00x
Receivables Turnover (TTM)7.53x
EV / Free Cash Flow (TTM)15.92x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.06
Receivables Turnover (Annual)7.53x
ROI (TTM)2.63%
P/S Ratio (TTM)4.43x
Pretax Margin (5Y Avg)-887.69%
Revenue / Share (Annual)$2.14
Tangible BV / Share (Annual)$-0.58
Price vs S&P 500 (52W)-41.07%
P/E Ratio (TTM)139.76x
Year-to-Date Return7.52%
5-Day Price Return3.92%
EPS Normalized (Annual)$0.07
ROA (5Y Avg)-87.52%
Net Profit Margin (Annual)3.17%
Month-to-Date Return17.03%
Cash Flow / Share (TTM)$-3.60
EBITD / Share (Annual)$0.02
Operating Margin (Annual)0.77%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)16.76x
ROI (5Y Avg)-82.27%
P/E Excl Extra (TTM)139.76x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.06
P/TBV (Quarterly)2.67x
P/B Ratio (Annual)3.21x
Inventory Turnover (TTM)1.37x
Pretax Margin (TTM)4.12%
Book Value / Share (Annual)$3.21
Price vs S&P 500 (13W)1.76%
Beta0.57x
P/FCF (Annual)18.00x
Revenue / Share (TTM)$2.34
ROE (TTM)2.63%
52-Week Low$8.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.23
4.23
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
DCTHDelcath Systems Inc | 4.43x | 120.10% | 86.16% | 0.77% | $10.88 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Delcath Systems develops a drug-device combination for treating primary and metastatic liver cancers. Its proprietary Melphalan Hepatic Delivery System administers high-dose chemotherapy directly to the liver while minimizing systemic exposure and associated side effects. The company manufactures and distributes its products across the United States and Europe.